CHICAGO, IL and Palo Alto, CA - June 18, 2000
Integrated Genomics, Inc. announced today it had signed a research and licensing agreement with Genencor International to perform work in the area of microbial genomics. Under the terms of the agreement, Integrated Genomics will analyze the bacterial genomes of interest to Genencor. Genencor will also license the Chicago-based company's genome analysis suite WIT-PRO™.
WIT-PRO™ is a discovery platform for functional annotation of sequence data, functional reconstruction, and modeling. This environment for performing comparative analysis of genomes consists of a database holding over 256 genomes and a database of the most comprehensive computerized source for enzymatic reactions in the world, with more than 21,000 entries of biochemical information. Integrated into WIT-PRO™ are also tools for functional genomic analysis that go beyond similarity search.
"We are very pleased to be working with Genencor International. The fit between Genencor's needs and Integrated Genomics' capabilities are excellent. This agreement further demonstrates the acceptance of our genomic approach and the power and uniqueness of our cross-genome analysis suite" said IG's CEO Michael Fonstein.
About Genencor International
Genencor International develops genetically based biotechnology products for the health care, agriculture and industrial chemical markets. The company has principal corporate offices in Palo Alto, Calif., Rochester, N.Y., and Leiden, the Netherlands.
About Integrated Genomics
Integrated Genomics, Inc., based in Chicago, Illinois, offers systematic approach to solving genomic problems by using pioneering methods of high-throughput sequencing, comparative analysis of genomes, functional reconstruction, and metabolic modeling. IG's analytical environment WIT-PRO™ holds a database of over 256 genomes and the largest biochemical database in the market. The company specializes in bacterial and fungal genomics and offers services for genome analysis and functional reconstruction with an aim to address issues such as strain and fermentation improvement.
Yuri Nikolski, Ph.D.
Vice President, Business Development